CareDx (NASDAQ:CDNA) Stock, Quote.Headers.trade-ideas

CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

Monitoring,Of,Patient's,Heart,In,Intensive,Care,Unit.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CDNA

HRTX

TMDX

Top 3 Health Care Stocks That May Crash In May

Macro,Shot,Of,Computer,Monitor,With,World,Stock,Market,Chart

Intraday Update

Movers

ACIC

ADMA

AEHL

AFRM

AKAM

ARRY

ARWR

BFRI

BROS

CLNE

DCBO

DIOD

EVLV

FLNC

FLUX

FNKO

FROG

FWRD

GRPN

GRTS

GWAV

HGAS

INSG

IOVA

ITOS

LIDR

MGNX

MLTX

MVIS

NGVC

NTRA

NVAX

NVTS

ORGO

OUST

PEGY

PGNY

RVNC

RWAY

SKIN

SKYT

SOUN

SRTS

YELP

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

xr:d:DAFkp-hoz7E:2,j:6946068668848083796,t:23060207

CARG

DOCN

Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday

CareDx Inc

CANADIAN TIRE LTD A by Canadian Tire Corp. Ltd.

Canadian Tire Corp Ltd

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CareDx, presenting an average target of $16.67, a high estimate of $22.00, and a low estimate of $14.00. This current average reflects an increase of 26.29% from the previous average price target of $13.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1721232035_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of CareDx's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CareDx</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>CareDx's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining CareDx's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -6.75% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CareDx's net margin is impressive, surpassing industry averages. With a net margin of -23.12%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CareDx's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.44% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): CareDx's ROA excels beyond industry benchmarks, reaching -3.62%. This signifies efficient management of assets and strong financial health.
Debt Management: CareDx's debt-to-equity ratio surpasses industry norms, standing at 0.13. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where CareDx Stands With Analysts

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $14 to $16.

Price Target

Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $16

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.5, a high estimate of $22.00, and a low estimate of $14.00. Observing a 26.92% increase, the current average has risen from the previous average price target of $13.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1717178476_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of CareDx by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CareDx's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering CareDx: A Closer Look</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>Understanding the Numbers: CareDx's Finances</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: CareDx's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -6.75%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CareDx's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -23.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CareDx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -6.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CareDx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.62% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: CareDx's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 6 Analyst Evaluations For CareDx

HC Wainwright &amp; Co. analyst Yi Chen reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on CareDx

CareDx solutions are featured in 36 oral presentations and posters, and a symposium. The findings highlight innovative approaches, including AI integration, and the real-world clinical utility of CareDx&#39;s solutions, emphasizing their significant impact on patient care and outcomes in kidney, heart, and lung transplantation.

CareDx To Present New Data At The 2024 American Transplant Congress Being Held June 1-5 In Philadelphia

WIIM

CareDx shares are trading lower. The company announced that it responded to Natera's filing of a motion for an injunction related to patent 11,111,544.

CareDx Reiterates Position that it Does Not Infringe Natera&#39;s &lsquo;544 Patent
Injunction Motion has No Impact on CareDx&#39;s Business or Patient and Clinician Access to AlloSure or AlloMap
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) &ndash; The Transplant Company&trade; focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers &ndash; today responded to Natera, Inc.&#39;s filing of a motion for an injunction related to patent 11,111,544 (the &lsquo;544 patent).
The motion seeks to stop CareDx from using a prior AlloSure&reg; process that Natera alleged infringed the &lsquo;544 patent. That process is no longer in effect. As CareDx informed Natera and the Court, since August 2023, CareDx has utilized a new AlloSure process that it believes does not infringe on the &lsquo;544 patent.
The underlying validity of the &lsquo;544 patent also remains subject to judicial review.
&quot;We believe the motion against a process that is no longer in effect is irrelevant, and the District Court is still considering the fundamental question of the validity of the &lsquo;544 patent,&quot; said John W. Hanna, CareDx President and CEO. &quot;We greatly appreciate the continued support of the transplant community as we seek to resolve these matters, allowing us to return our full attention to serving patients and developing clinical innovations that improve transplant care.&quot;
Natera has previously claimed infringement on three patents:
<ol>
<li>Prior to trial, the District Court dismissed patent 10,597,724 (the &lsquo;724 patent) as invalid as patent ineligible.</li>
<li>At trial, CareDx was found not to have infringed on patent 10,655,180 (the &lsquo;180 patent).</li>
<li>The &lsquo;544 patent is the subject of post-trial motion practice in which, among other things, CareDx is seeking to invalidate that patent on the same grounds as the &lsquo;724 patent.</li>
</ol>
Natera&#39;s motion does not impact CareDx&#39;s business or ability to continue providing transplant patients with AlloSure or AlloMap&reg;.

Biotech

Legal

General

CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New AlloSure Process That It Believes Does Not Infringe On The '544 Patent.

As of May 24, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul>
<li>On April 30, TransMedics posted upbeat quarterly results and raised its 2024 guidance. &#8220;We are pleased with our first quarter results as we simultaneously drove continued revenue growth, expanded our infrastructure, and achieved profitability,&#8221; said Waleed Hassanein, MD, President and Chief Executive Officer. The company's stock gained around 55% over the past month and has a <a href="https://www.benzinga.com/quote/TMDX">52-week high of $142.30</a>.</li>
<li>RSI Value: 78.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TMDX Price Action: Shares of TransMedics rose 0.4% to close at $137.53 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</h3>
<ul>
<li>On May 9, CareDX reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates. &#8220;We set a new baseline in our Testing Services business in the second half of 2023 and are back to delivering sequential growth. I am pleased with the team&#8217;s strong performance across all businesses this quarter,&#8221; said John W. Hanna, CareDx President and CEO. The company's stock gained around 98% over the past month and <a href="https://www.benzinga.com/quote/CDNA">has a 52-week high</a> of $16.54.</li>
<li>RSI Value: 76.48</li>
<li>CDNA Price Action: Shares of CareDx rose 1.7% to close at $15.83 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>)</h3>
<ul>
<li>On May 7, Heron Therapeutics reported better-than-expected first-quarter financial results and reaffirmed its FY24 revenue guidance. &#8220;We are extremely pleased with our ability to improve the financial efficiency of the business by growing revenues, improving margins, and reducing expenses. We made tremendous progress this quarter by promptly training CrossLink sales representatives and integrating them into our commercial execution, while also training our own commercial team on the newly expanded label for ZYNRELEF,&#8221; said Craig Collard, Chief Executive Officer of Heron. The company's stock gained around 31% over the past month and has a <a href="https://www.benzinga.com/quote/HRTX">52-week high</a> of $3.59.</li>
<li>RSI Value: 71.77</li>
<li>HRTX Price Action: Shares of Heron Therapeutics closed at $3.47 on Thursday.</li>
</ul>
Read This Next: <a href="https://www.benzinga.com/news/24/05/38984382/slb-first-solar-and-2-other-stocks-insiders-are-selling">SLB, First Solar And 2 Other Stocks Insiders Are Selling</a>

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $15 to $22.

Craig-Hallum Maintains Buy on CareDx, Raises Price Target to $22

HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection
Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive Results
Two-Year Clinical Outcomes Data Demonstrate Excellent Survival and Allograft Function
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) – The Transplant Company&#x2122; – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.jhltonline.org%252Farticle%252FS1053-2498%252824%252901659-0%252Ffulltext%26data%3D05%257C02%257C%257C069254bb096f45ad279b08dc74f1a091%257C9ec77d4e480144b4b8fea5749eaf06b0%257C1%257C0%257C638513828360488587%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C0%257C%257C%257C%26sdata%3DJbjSFqIg6M3pR7YfHuZhUh3Sln0W%252FoUtJF11tLtbjqc%253D%26reserved%3D0&amp;esheet=54000312&amp;newsitemid=20240516103531&amp;lan=en-US&amp;anchor=The+Journal+of+Heart+and+Lung+Transplantation&amp;index=1&amp;md5=121d560a78207a51f87ddef06b43362d">The Journal of Heart and Lung Transplantation</a>.
The prospective observational study demonstrates that HeartCare&#xAE; which combines AlloSure&#xAE; Heart donor-derived cell-free DNA (dd-cfDNA) and AlloMap&#xAE; Heart gene-expression profiling (GEP), identifies acute cellular rejection in heart transplant patients better than dd-cfDNA testing alone and is associated with fewer biopsies and excellent clinical outcomes.1

CareDx Presents Findings from The SHORE Study, HeartCare Outperforms dd-cfDNA Alone In Identifying Rejection And Patients Experienced Fewer Biopsies

Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.4, along with a high estimate of $18.00 and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 24.9% from the previous average price target of $12.33.
<img src="https://www.benzinga.com/files/images/story/2024/1715634032_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into CareDx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into CareDx's Background</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>Key Indicators: CareDx's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, CareDx faced challenges, resulting in a decline of approximately -20.41% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CareDx's net margin is impressive, surpassing industry averages. With a net margin of -180.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CareDx's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -36.03%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): CareDx's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -24.4%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.13, CareDx adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 5 Analyst Ratings For CareDx

Raymond James analyst Andrew Cooper downgrades CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) from Outperform to Market Perform.

Downgrades

Raymond James Downgrades CareDx to Market Perform

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $10 to $14.

Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $14

Stephens &amp; Co. analyst Mason Carrico maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Overweight and raises the price target from $15 to $18.

Stephens & Co. Maintains Overweight on CareDx, Raises Price Target to $18

Shares of Diodes Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/DIOD/earnings">quarterly financial results</a>.
Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Diodes shares dipped 9.8% to $68.99 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) gained 40% to $17.06 after the company announced a $120 million registered direct offering and reported Q1 financial results.</li>
<li>AEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) shares climbed 39.8% to $1.65 after the company disclosed a partnership with LITEON Technology Corporation.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) shares climbed 39.4% to $32.86 after the company reported better-than-expected first-quarter sales results.</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) gained 34.3% to $13.90 after the company reported better-than-expected first-quarter financial results.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) rose 32% to $3.02 following upbeat quarterly results.</li>
<li>Inseego Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) gained 31.4% to $5.05 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) surged 26.3% to $13.99 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Sensus Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) shares rose 22.5% to $4.6699 after the company reported better-than-expected first-quarter financial results.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) gained 22.3% to $12.85 after the company reported better-than-expected first-quarter results.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) jumped 21.8% to $1.90 after the company reported better-than-expected quarterly GAAP EPS results.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) rose 21% to $8.39 after the company reported better-than-expected first-quarter financial results and issued strong revenue guidance.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares gained 19.3% to $5.66 in pre-market trading after the company reported better-than-expected first quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) rose 17.2% to $12.79 after the company reported better-than-expected first quarter financial results. The company announced the sale of 100% of its issued and outstanding stock of Interboro Insurance Company to Forza Insurance Holdings.</li>
<li>Global Gas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGAS#NASDAQ">HGAS</a>) rose 15.3% to $1.28.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) gained 15% to $23.42 after the company reported better-than-expected quarterly earnings and authorized a $3 billion share repurchase program.</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) gained 14.6% to $1,478.49 after the company reported better-than-expected first-quarter financial results and issued guidance.</li>
<li>SkyWater Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) rose 14.4% to $7.61.</li>
<li>Clean Energy Fuels Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) climbed 13.6% to $2.74 following upbeat quarterly results.</li>
<li>Natural Grocers by Vitamin Cottage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NASDAQ">NGVC</a>) gained 13.2% to $20.19 following second-quarter results.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) rose 11.3% to $106.36 following strong first-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) jumped 11% to $6.50 following first-quarter results.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) gained 8.8% to $9.12 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) jumped 8.7% to $35.68 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $33 to $46.</li>
<li>Funko Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) gained 7% to $7.30 as the company reported better-than-expected first-quarter earnings and issued strong earnings forecast for the second quarter. The company also appointed Cynthia Williams as its Chief Executive Officer, effective May 20.</li>
<li>Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) gained 6.8% to $34.26 after the company reported better-than-expected first-quarter financial results and raised its FY24 EPS range.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares rose 3.5% to $12.94 after the company reported stronger-than-expected financial results for the first quarter on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) shares fell 73.4% to $3.9089 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) fell 37.2% to $0.0439 after jumping 20% on Thursday.</li>
<li>Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) dipped 35.8% to $2.9350 after the company reported worse-than-expected quarterly financial results.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) fell 29.3% to $1.30 after the company announced second half and full year 2023 financial results.</li>
<li>Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) fell 29.2% to $2.7290 after the company reported worse-than-expected first-quarter financial results and lowered its FY24 sales guidance below estimates.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) fell 27% to $3.0950 as the company posted a loss for its first quarter on Thursday.</li>
<li>Biofrontera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) fell 26.6% to $1.16.</li>
<li>American Vanguard Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) dipped 22.2% to $9.84 following weak quarterly results.</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) dipped 22% to $0.25.</li>
<li>The Beauty Health Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) fell 22% to $2.80 following quarterly results.</li>
<li>MicroVision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) shares fell 21.6% to $1.27 after the company reported worse-than-expected first-quarter GAAP EPS results.</li>
<li>Progyny, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) shares fell 21.5% to $25.51 after the company reported worse-than-expected first-quarter sales results and issued FY24 sales guidance below estimates.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares declined 20.7% to $0.0579 after the company reported worse-than-expected first quarter financial results.</li>
<li>The E.W. Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) dipped 19.7% to $3.71 following quarterly results.</li>
<li>CS Disco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) fell 19.6% to $6.50 following weak sales.</li>
<li>Safe and Green Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGD#NASDAQ">SGD</a>) shares fell 18.4% to $0.6937 after jumping around 37% on Thursday.</li>
<li>Docebo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) fell 18.2% to $37.99.</li>
<li>JFrog Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) shares fell 17.7% to $33.43 after the company reported first quarter financial results.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) shares fell 17.3% to $0.7606 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) fell 15.6% to $11.35 following first-quarter financial results.</li>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares declined 14.4% to $0.8320 after the company reported worse-than-expected first quarter GAAP EPS results.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) shares fell 12.8% to $4.0850 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) declined 12.2% to $14.72.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) fell 11.1% to $21.97 after the company reported second-quarter financial results.</li>
<li>AMN Healthcare Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) fell 9.5% to $55.08 following first-quarter results.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) fell 8.4% to $24.69 after the company reported first-quarter financial results.</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) fell 8.1% to $94.16 after the company issued weak guidance.</li>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) declined 7.8% to $17.28 following second-quarter financial results.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) dipped 7.4% to $3.3399.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) fell 7% to $39.02.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) fell 5% to $33.13. BMO Capital analyst James Fotheringham maintained Affirm with a Market Perform and lowered the price target from $48 to $46.</li>
<li>Runway Growth Finance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) shares fell 4.1% to $11.61 as the company priced its secondary offering of 3.75 million common stock by selling stockholder at $11.50 per share.</li>
<li>Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) shares declined 3.6% to $38.20 after the company reported a first-quarter revenue miss.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38760794/bitcoin-tops-63-000-akash-network-emerges-as-top-gainer">Bitcoin Tops $63,000; Akash Network Emerges As Top Gainer</a>

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

U.S. stocks were mostly higher, with the Dow Jones gaining over 100 points on Friday.
Shares of Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/G/earnings">raised its FY24 EPS range</a>.
Genpact posted adjusted earnings of 73 cents per share, beating market estimates of 68 cents per share. The company's quarterly sales came in at $1.13 billion versus expectations of $1.11 billion, according to data from<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro</a>.
Genpact shares gained 6.8% to $34.26 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares gained 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and develop COVID-influenza combination vaccines.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) rose 40% to $17.06 after the company announced a $120 million registered direct offering and reported Q1 financial results.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) shares jumped 39.4% to $32.86 after the company reported better-than-expected first-quarter sales results.</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) rose 34.3% to $13.90 after the company reported better-than-expected first-quarter financial results.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) gained 32% to $3.02 following upbeat quarterly results.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) gained 26.3% to $13.99 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) climbed 22.3% to $12.85 after the company reported better-than-expected first-quarter results.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) climbed 21% to $8.39 after the company reported better-than-expected first-quarter financial results and issued strong revenue guidance.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares rose 19.3% to $5.66 in pre-market trading after the company reported better-than-expected first quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) gained 17.2% to $12.79 after the company reported better-than-expected first quarter financial results. The company announced the sale of 100% of its issued and outstanding stock of Interboro Insurance Company to Forza Insurance Holdings.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) rose 15% to $23.42 after the company reported better-than-expected quarterly earnings and authorized a $3 billion share repurchase program.</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) rose 14.6% to $1,478.49 after the company reported better-than-expected first-quarter financial results and issued guidance.</li>
<li>Clean Energy Fuels Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) gained 13.6% to $2.74 following upbeat quarterly results.</li>
<li>Natural Grocers by Vitamin Cottage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NASDAQ">NGVC</a>) climbed 13.2% to $20.19 following second-quarter results.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) gained 11.3% to $106.36 following strong first-quarter earnings.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) rose 11% to $6.50 following first-quarter results.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) climbed 8.8% to $9.12 after the company reported better-than-expected first-quarter sales results and issued FY24 revenue guidance above estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) rose 8.7% to $35.68 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $33 to $46.</li>
<li>H&amp;R Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) gained 7.5% to $52.89 after the company reported better-than-expected quarterly financial results.</li>
<li>RB Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) gained 7.3% to $78.24 after the company reported better-than-expected first-quarter financial results.</li>
<li>Funko Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) rose 7% to $7.30 as the company reported better-than-expected first-quarter earnings and issued strong earnings forecast for the second quarter. The company also appointed Cynthia Williams as its Chief Executive Officer, effective May 20.</li>
<li>DigitalOcean Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) gained 6.9% to $34.82 following better-than-expected first-quarter earnings and upbeat guidance.</li>
<li>Nelnet, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNI#NYSE">NNI</a>) gained 6.4% to $104.94 after the company reported better-than-expected earnings results.</li>
<li>CarGurus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) rose 6.3% to $23.68 after the company reported mixed first-quarter financial results.</li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) gained 5.7% to $123.36 after the company reported mixed quarterly financial results.</li>
<li>The Boston Beer Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) gained 4.1% to $296.21.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares gained 3.5% to $12.94 after the company reported stronger-than-expected financial results for the first quarter on Thursday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38759656/delta-air-lines-live-nation-entertainment-and-more-on-cnbcs-final-trades">Delta Air Lines, Live Nation Entertainment And More On CNBC&#8217;s &#8216;Final Trades</a>&#8216;

CareDX shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY24 revenue guidance above estimates.

Guidance

CareDx Sees FY24 Revenue $274M-$282M Vs $266.955M Est.

CareDx rises as much as 38%, highest intraday gain in six years

CareDx cut to market perform by Raymond James over valuation

CareDx (CDNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 10. Analyst Matthew Sykes from Goldma...

Buy Rating Justified: CareDx's Strong Financial Performance and Market Potential

H.C. Wainwright analyst Yi Chen has reiterated their neutral stance on CDNA stock, giving a Hold rating yesterday. Yi Chen has given his Hold ratin...

Balanced Outlook for CareDx: Strong Performance Amid Rising Competition

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CARGO Therapeutics, Inc. (CRGX – Research Report), CareDx (CDNA –...

Analysts' Opinions Are Mixed on These Healthcare Stocks: CARGO Therapeutics, Inc. (CRGX), CareDx (CDNA) and Nuvation Bio (NUVB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CareDx (CDNA – Research Report), Amgen (AMGN – Research Report) a...

Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Amgen (AMGN) and Orasure Technologies (OSUR)

H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx (CDNA – Research Report) today. The company's shares opened today at $13.64. Che...

CareDx (CDNA) Gets a Hold from H.C. Wainwright

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inotiv (NOTV – Research Report), Dexcom (DXCM – Rese...

Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Dexcom (DXCM) and CareDx (CDNA)

CareDx: Benefiting From Some Certainty

Small-Cap Stocks 2024 Second Half Outlook - Buy Small Caps

ACLS

AMGN

AMSC

AOSL

ASPN

CECO

CLBT

CLBTW

CRGX

DXCM

ENVX

HIMS

NOTV

NUVB

OSUR

PLSE

PRCT

RXST

TWST

VERX

WGSWW

Press Releases

CareDx to Report First Quarter 2024 Financial Results

CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CareDx Reports First Quarter 2024 Results

Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

CareDx to Participate in Upcoming Investor Conferences

CareDx Reiterates Position that it Does Not Infringe the '544 Patent, Injunction Motion is Irrelevant

AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress

Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients

CareDx to Report Second Quarter 2024 Financial Results

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

CareDx

CareDx (CDNA) Forecast

CareDx (NASDAQ:CDNA) Stock, Quote.Headers.trade-ideas